Sang Chul Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sang Chul Park has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Hoon Kim
Department of Otorhinolaryngology Yonsei University College of Medicine Seoul Republic of Korea
5 shared publications - Joo-Heon Yoon
Yonsei University College of Medicine
4 shared publications - Yeeun Bak
Department of Microbiology, Yonsei University College of Medicine, Seoul, Korea
4 shared publications - Dahee Shim
Hallym University
3 shared publications - Do-Yang Park
Department of Otolaryngology, Ajou University School of Medicine, Suwon 16499, Republic of Korea
3 shared publications - Hongmin Kim
Department of Microbiology, Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, South Korea
3 shared publications
Latest Publications
- 27 January 2026
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 40 (4) , 269-278
Reduced Numbers of Blood Dendritic Cell Antigen 3 Positive Dendritic Cells in the Nasal Mucosa Contribute to Severe Inflammation in Patients with Allergic Rhinitis and Chronic Rhinosinusitis
Background: Dendritic cells (DCs) are antigen-presenting cells that play a critical role in airway diseases by initiating and regulating immune responses. DCs are classified into plasmacytoid DCs (pDCs) and conventional DCs (cDCs), with the cDC lineage further divided into cDC1 and cDC2 subsets. Each subset exhibits distinct functions in immune regulation and disease pathogenesis. Thus, analyzing DC subsets is crucial for understanding the pathogenesis of airway diseases with diverse endotypes. Objective: Allergic rhinitis (AR) and chronic rhinosinusitis (CRS), further divided into eosinophilic CRS (ECRS) and non-eosinophilic CRS (NECRS), are typical upper airway diseases with diverse endotypes. AR and CRS often occur simultaneously, and their severity tends to increase when they are comorbid. To understand the endotypes of AR and CRS, we classified the presence or absence of AR and CRS, analyzed the changes in DC subsets in the nasal mucosa, and compared these results with clinical features. Methods: Nasal polyp tissues and ethmoid mucosa were collected from 42 patients who underwent endoscopic sinus surgery. DC were analyzed by flow cytometry to detect the expression of blood DC antigen (BDCA)-1, BDCA-2, and BDCA-3. Results: BDCA-3 + cDC levels were significantly reduced in patients with both AR and CRS, compared to those with AR alone or CRS alone. This reduction was especially prominent in patients with ECRS, polysensitization, and total serum IgE ≥ 200 IU/mL. BDCA-3 + cDC levels were also inversely correlated with preoperative computed tomography scores and serum eosinophil and immunoglobulin E levels. Conclusion: BDCA-3 + cDC levels may be involved in mucosal immune regulation and are associated with increased disease burden in patients with comorbid AR and ECRS.
- 27 January 2026
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 40 (4) , 269-278
Reduced Numbers of Blood Dendritic Cell Antigen 3 Positive Dendritic Cells in the Nasal Mucosa Contribute to Severe Inflammation in Patients with Allergic Rhinitis and Chronic Rhinosinusitis
Background: Dendritic cells (DCs) are antigen-presenting cells that play a critical role in airway diseases by initiating and regulating immune responses. DCs are classified into plasmacytoid DCs (pDCs) and conventional DCs (cDCs), with the cDC lineage further divided into cDC1 and cDC2 subsets. Each subset exhibits distinct functions in immune regulation and disease pathogenesis. Thus, analyzing DC subsets is crucial for understanding the pathogenesis of airway diseases with diverse endotypes. Objective: Allergic rhinitis (AR) and chronic rhinosinusitis (CRS), further divided into eosinophilic CRS (ECRS) and non-eosinophilic CRS (NECRS), are typical upper airway diseases with diverse endotypes. AR and CRS often occur simultaneously, and their severity tends to increase when they are comorbid. To understand the endotypes of AR and CRS, we classified the presence or absence of AR and CRS, analyzed the changes in DC subsets in the nasal mucosa, and compared these results with clinical features. Methods: Nasal polyp tissues and ethmoid mucosa were collected from 42 patients who underwent endoscopic sinus surgery. DC were analyzed by flow cytometry to detect the expression of blood DC antigen (BDCA)-1, BDCA-2, and BDCA-3. Results: BDCA-3 + cDC levels were significantly reduced in patients with both AR and CRS, compared to those with AR alone or CRS alone. This reduction was especially prominent in patients with ECRS, polysensitization, and total serum IgE ≥ 200 IU/mL. BDCA-3 + cDC levels were also inversely correlated with preoperative computed tomography scores and serum eosinophil and immunoglobulin E levels. Conclusion: BDCA-3 + cDC levels may be involved in mucosal immune regulation and are associated with increased disease burden in patients with comorbid AR and ECRS.
- Open Access
- 10 July 2025
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 68 (7) , 427-435
Medications and new therapies for chronic rhinosinusitis: a narrative review
Purpose: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease of the upper airways, encompassing distinct endotypes and phenotypes. Among these, chronic rhinosinusitis with nasal polyps (CRSwNP) frequently involves type 2 inflammation and tends to recur despite conventional treatments. This review aims to summarize current pharmacologic strategies for CRS management, with a focus on the emerging role of biologics as precision medicine.Current Concepts: Standard pharmacologic treatments for CRS include saline irrigation, intranasal corticosteroids, short-term systemic steroids, macrolide antibiotics, leukotriene antagonists, and, in select cases, bacterial lysates. These therapies target mucosal inflammation and symptom relief, often serving as adjuncts to endoscopic sinus surgery. Recently, biologics such as dupilumab, omalizumab, and mepolizumab have been approved for CRSwNP, offering targeted inhibition of the interleukin (IL)-4/IL-13, immunoglobulin E, and IL-5 pathways, respectively. Clinical trials and real-world studies have demonstrated their efficacy in reducing polyp size, improving quality of life, restoring olfaction, and reducing the need for surgery in type 2 inflammation-dominant CRSwNP.Discussion and Conclusion: Biologics represent a paradigm shift in the management of CRS, particularly in refractory CRSwNP. However, issues regarding cost, insurance coverage, optimal treatment duration, and criteria for switching or discontinuation remain unresolved. Future research should focus on identifying predictive biomarkers, establishing practical guidelines specific to Korea, and validating the real-world cost-effectiveness of these guidelines. A personalized treatment strategy based on endotype classification, that integrates pharmacologic and biologic therapies, may improve long-term outcomes in patients with CRS.
- 10 July 2025
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 68 (7) , 427-435
Open AccessMedications and new therapies for chronic rhinosinusitis: a narrative review
Purpose: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease of the upper airways, encompassing distinct endotypes and phenotypes. Among these, chronic rhinosinusitis with nasal polyps (CRSwNP) frequently involves type 2 inflammation and tends to recur despite conventional treatments. This review aims to summarize current pharmacologic strategies for CRS management, with a focus on the emerging role of biologics as precision medicine.Current Concepts: Standard pharmacologic treatments for CRS include saline irrigation, intranasal corticosteroids, short-term systemic steroids, macrolide antibiotics, leukotriene antagonists, and, in select cases, bacterial lysates. These therapies target mucosal inflammation and symptom relief, often serving as adjuncts to endoscopic sinus surgery. Recently, biologics such as dupilumab, omalizumab, and mepolizumab have been approved for CRSwNP, offering targeted inhibition of the interleukin (IL)-4/IL-13, immunoglobulin E, and IL-5 pathways, respectively. Clinical trials and real-world studies have demonstrated their efficacy in reducing polyp size, improving quality of life, restoring olfaction, and reducing the need for surgery in type 2 inflammation-dominant CRSwNP.Discussion and Conclusion: Biologics represent a paradigm shift in the management of CRS, particularly in refractory CRSwNP. However, issues regarding cost, insurance coverage, optimal treatment duration, and criteria for switching or discontinuation remain unresolved. Future research should focus on identifying predictive biomarkers, establishing practical guidelines specific to Korea, and validating the real-world cost-effectiveness of these guidelines. A personalized treatment strategy based on endotype classification, that integrates pharmacologic and biologic therapies, may improve long-term outcomes in patients with CRS.
- Open Access
- 8 July 2025
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (5) , 101661
Association of tinnitus with obstructive sleep apnea and rapid eye movement-related obstructive sleep apnea in similar hearing threshold groups
- 8 July 2025
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (5) , 101661
Open AccessAssociation of tinnitus with obstructive sleep apnea and rapid eye movement-related obstructive sleep apnea in similar hearing threshold groups
- Open Access
Vitamin D Deficiency as a Contributing Factor to Chronic Rhinitis in Middle-Aged and Older Adults: An Epidemiological Study
Background: Recent studies suggest a critical role for vitamin D in respiratory diseases, including asthma and allergic rhinitis. However, the relationship between vitamin D deficiency and chronic rhinitis, particularly in middle- and older-aged populations, remains underexplored. This study aimed to investigate the association between vitamin D deficiency and chronic rhinitis in middle- and older-aged adults while controlling for lifestyle and physical status factors. Methods: Data from 12,654 participants aged 40 years and older were analyzed from the fifth Korean National Health and Nutrition Examination Survey (2010–2012). The prevalence of chronic rhinitis and its association with serum vitamin D levels were assessed using multiple logistic regression models, adjusting for demographic, lifestyle, and physical characteristics. Results: The prevalence of chronic rhinitis was 21.1%. Participants with chronic rhinitis had a higher prevalence of vitamin D deficiency (69.9% vs. 65.2%) and lower mean vitamin D levels (17.73 ng/mL vs. 18.19 ng/mL) compared to those without chronic rhinitis. After adjusting for confounding factors, vitamin D deficiency remained significantly associated with an increased likelihood of chronic rhinitis (OR = 1.21, 95% CI, 1.082–1.348, p = 0.001). Conclusions: This study identifies a significant association between vitamin D deficiency and chronic rhinitis in middle- and older-aged adults, suggesting that maintaining adequate vitamin D levels may be important in managing chronic rhinitis.
Open AccessVitamin D Deficiency as a Contributing Factor to Chronic Rhinitis in Middle-Aged and Older Adults: An Epidemiological Study
Background: Recent studies suggest a critical role for vitamin D in respiratory diseases, including asthma and allergic rhinitis. However, the relationship between vitamin D deficiency and chronic rhinitis, particularly in middle- and older-aged populations, remains underexplored. This study aimed to investigate the association between vitamin D deficiency and chronic rhinitis in middle- and older-aged adults while controlling for lifestyle and physical status factors. Methods: Data from 12,654 participants aged 40 years and older were analyzed from the fifth Korean National Health and Nutrition Examination Survey (2010–2012). The prevalence of chronic rhinitis and its association with serum vitamin D levels were assessed using multiple logistic regression models, adjusting for demographic, lifestyle, and physical characteristics. Results: The prevalence of chronic rhinitis was 21.1%. Participants with chronic rhinitis had a higher prevalence of vitamin D deficiency (69.9% vs. 65.2%) and lower mean vitamin D levels (17.73 ng/mL vs. 18.19 ng/mL) compared to those without chronic rhinitis. After adjusting for confounding factors, vitamin D deficiency remained significantly associated with an increased likelihood of chronic rhinitis (OR = 1.21, 95% CI, 1.082–1.348, p = 0.001). Conclusions: This study identifies a significant association between vitamin D deficiency and chronic rhinitis in middle- and older-aged adults, suggesting that maintaining adequate vitamin D levels may be important in managing chronic rhinitis.
- Open Access
- 21 April 2024
- Published by Elsevier in Journal of Ginseng Research
- Vol. 48 (4) , 354-365
Effects of Panax species and their bioactive components on allergic airway diseases
- 21 April 2024
- Published by Elsevier in Journal of Ginseng Research
- Vol. 48 (4) , 354-365
Open AccessEffects of Panax species and their bioactive components on allergic airway diseases
- Open Access
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (2) , 145-159
KAAACI Allergic Rhinitis Guidelines: Part 2. Update in Non-pharmacological Management
Park DY, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):145-159. https://doi.org/10.4168/aair.2023.15.2.145
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (2) , 145-159
Open AccessKAAACI Allergic Rhinitis Guidelines: Part 2. Update in Non-pharmacological Management
Park DY, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):145-159. https://doi.org/10.4168/aair.2023.15.2.145
- Open Access
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (1) , 19-31
KAAACI Allergic Rhinitis Guidelines: Part 1. Update in Pharmacotherapy
Yang SI, et al. Allergy Asthma Immunol Res. 2023 Jan;15(1):19-31. https://doi.org/10.4168/aair.2023.15.1.19
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (1) , 19-31
Open AccessKAAACI Allergic Rhinitis Guidelines: Part 1. Update in Pharmacotherapy
Yang SI, et al. Allergy Asthma Immunol Res. 2023 Jan;15(1):19-31. https://doi.org/10.4168/aair.2023.15.1.19
- Open Access
- 21 June 2022
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
- Vol. 65 (6) , 309-318
Understanding the Mouse Model of Respiratory Allergic Diseases
Respiratory allergic diseases, represented by allergic rhinitis and asthma, show various features due to their complex pathophysiology. Mouse models of respiratory allergic diseases replicate the characteristics of human allergic rhinitis and asthma, including airway inflammation airway hyperresponsiveness. Different phenotypes and immunologic features are shown according to the various strain of mouse; C57BL/6 strain and BALB/c strain are commonly used in allergic rhinitis and asthma. Ovalbumin as well as pathophysiologically relevant allergen, including house dust mite and fungus are generally used. The mouse model protocols usually include allergen sensitization period followed by allergen provocation period. Allergens possibly combined with adjuvant are introduced into mouse via intraperitoneal, subcutaneous, or intranasal route (sensitization period). Then, mouse repetitively inhales allergen by intranasal, intratracheal, or nebulized formation (aerosol), resulting in a robust influx of inflammatory cells in the airways (provocation period). We can evaluate several parameters including nasal rubbing and sneezing count, airway hyperresponsiveness, histological assessment, cellular composition, cytokine expression of nasal and lung tissue, and allergenspecific immunoglobulin of serum. These examinations provide useful information to understand the pathogenesis of allergic rhinitis and asthma and to test the safety and efficacy of new therapeutic agents. The present review analyzes several protocols and considerations as well as similarities and differences of mouse model of allergic rhinitis and asthma in detail.
- 21 June 2022
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
- Vol. 65 (6) , 309-318
Open AccessUnderstanding the Mouse Model of Respiratory Allergic Diseases
Respiratory allergic diseases, represented by allergic rhinitis and asthma, show various features due to their complex pathophysiology. Mouse models of respiratory allergic diseases replicate the characteristics of human allergic rhinitis and asthma, including airway inflammation airway hyperresponsiveness. Different phenotypes and immunologic features are shown according to the various strain of mouse; C57BL/6 strain and BALB/c strain are commonly used in allergic rhinitis and asthma. Ovalbumin as well as pathophysiologically relevant allergen, including house dust mite and fungus are generally used. The mouse model protocols usually include allergen sensitization period followed by allergen provocation period. Allergens possibly combined with adjuvant are introduced into mouse via intraperitoneal, subcutaneous, or intranasal route (sensitization period). Then, mouse repetitively inhales allergen by intranasal, intratracheal, or nebulized formation (aerosol), resulting in a robust influx of inflammatory cells in the airways (provocation period). We can evaluate several parameters including nasal rubbing and sneezing count, airway hyperresponsiveness, histological assessment, cellular composition, cytokine expression of nasal and lung tissue, and allergenspecific immunoglobulin of serum. These examinations provide useful information to understand the pathogenesis of allergic rhinitis and asthma and to test the safety and efficacy of new therapeutic agents. The present review analyzes several protocols and considerations as well as similarities and differences of mouse model of allergic rhinitis and asthma in detail.
- 1 April 2022
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 75 (4) , 1447-1454
Effectiveness of cross-linked human acellular dermal matrix in primary and revision augmentation rhinoplasty
- 1 April 2022
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 75 (4) , 1447-1454
Effectiveness of cross-linked human acellular dermal matrix in primary and revision augmentation rhinoplasty
- Open Access
A Cross-Sectional Study for Association between Periodontitis and Benign Prostatic Hyperplasia Using the Korean Genome and Epidemiology Study Data
Recently, several studies have suggested the relationship between periodontitis and prostatic disease. However, epidemiological studies on the association between periodontitis and benign prostatic hyperplasia (BPH) are scarce. Hence, we aimed to identify the association between the two diseases using data from the Korean Genome and Epidemiology Study. Among the 173,209 participants, 3297 men with periodontitis and 35,292 controls (without periodontitis) were selected. The history of BPH in participants with periodontitis and the controls were also investigated. Two-tailed analyses, independent t-tests, and chi-square tests were used for statistical analysis. The adjusted odds ratio (OR) for BPH was 1.50 (95% confidence interval, 1.35–1.68; p < 0.001) after adjusting for past medical histories. The adjusted OR for BPH was 1.57 (95% confidence interval, 1.41–1.76; p < 0.001) after adjusting for anthropometric and laboratory data. Collectively, this study provides evidence that periodontitis is associated with BPH. This finding supports the use of regular dental checkups and periodontal treatments to reduce the prevalence and progression of BPH.
Open AccessA Cross-Sectional Study for Association between Periodontitis and Benign Prostatic Hyperplasia Using the Korean Genome and Epidemiology Study Data
Recently, several studies have suggested the relationship between periodontitis and prostatic disease. However, epidemiological studies on the association between periodontitis and benign prostatic hyperplasia (BPH) are scarce. Hence, we aimed to identify the association between the two diseases using data from the Korean Genome and Epidemiology Study. Among the 173,209 participants, 3297 men with periodontitis and 35,292 controls (without periodontitis) were selected. The history of BPH in participants with periodontitis and the controls were also investigated. Two-tailed analyses, independent t-tests, and chi-square tests were used for statistical analysis. The adjusted odds ratio (OR) for BPH was 1.50 (95% confidence interval, 1.35–1.68; p < 0.001) after adjusting for past medical histories. The adjusted OR for BPH was 1.57 (95% confidence interval, 1.41–1.76; p < 0.001) after adjusting for anthropometric and laboratory data. Collectively, this study provides evidence that periodontitis is associated with BPH. This finding supports the use of regular dental checkups and periodontal treatments to reduce the prevalence and progression of BPH.